Abstract
The carbonic anhydrases (CAs, EC 4.2.1.1) are zinc containing metalloenzymes which catalyse efficiently the reversible hydration of carbon dioxide to bicarbonate with discharge of a proton, playing important physiological and physiopathological functions. To date, 16 different carbonic anhydrase isoforms have been described in higher vertebrates, including humans, and some of them have been considered as important targets for inhibitors with therapeutic applications. The catalytic and structural role of zinc in these enzyme are understood in great detail, and this provided molecular basis for the design of potent inhibitors, some of which possessing important clinical applications mainly as topically acting anti-glaucoma drugs, anticancer or antiobesity agents. The metal binding function is a critically important factor in the development of isozyme-specific and organ-selective inhibitors. Discovery of compounds that possess zinc binding function different from that of the classical one (sulfonamide type) is in constant progress and can offer opportunities for developing novel pharmacological agents. In the present review we will discuss the different zinc binding function reported in the literature up to now in the design of carbonic anhydrase inhibitors.
Keywords: Zinc binding functions, sulfamate, tumors, classical cytosolic isoforms, Urea
Current Topics in Medicinal Chemistry
Title: Metal Binding Functions in the Design of Carbonic Anhydrase Inhibitors
Volume: 7 Issue: 9
Author(s): Jean-Yves Winum, Andrea Scozzafava, Jean-Louis Montero and Claudiu T. Supuran
Affiliation:
Keywords: Zinc binding functions, sulfamate, tumors, classical cytosolic isoforms, Urea
Abstract: The carbonic anhydrases (CAs, EC 4.2.1.1) are zinc containing metalloenzymes which catalyse efficiently the reversible hydration of carbon dioxide to bicarbonate with discharge of a proton, playing important physiological and physiopathological functions. To date, 16 different carbonic anhydrase isoforms have been described in higher vertebrates, including humans, and some of them have been considered as important targets for inhibitors with therapeutic applications. The catalytic and structural role of zinc in these enzyme are understood in great detail, and this provided molecular basis for the design of potent inhibitors, some of which possessing important clinical applications mainly as topically acting anti-glaucoma drugs, anticancer or antiobesity agents. The metal binding function is a critically important factor in the development of isozyme-specific and organ-selective inhibitors. Discovery of compounds that possess zinc binding function different from that of the classical one (sulfonamide type) is in constant progress and can offer opportunities for developing novel pharmacological agents. In the present review we will discuss the different zinc binding function reported in the literature up to now in the design of carbonic anhydrase inhibitors.
Export Options
About this article
Cite this article as:
Winum Jean-Yves, Scozzafava Andrea, Montero Jean-Louis and Supuran T. Claudiu, Metal Binding Functions in the Design of Carbonic Anhydrase Inhibitors, Current Topics in Medicinal Chemistry 2007; 7 (9) . https://dx.doi.org/10.2174/156802607780636771
DOI https://dx.doi.org/10.2174/156802607780636771 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aggregation-Induced Emission of Tetraarylethene Luminogens
Current Organic Chemistry Gastrin-Releasing Peptide as a Molecular Target for Inflammatory Diseases: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Current Medicinal Chemistry Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Somatic Genomic Variations in Extra-Embryonic Tissues
Current Genomics Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy
Current Drug Metabolism Clinically Relevant Reprogramming to Pluripotency
Recent Patents on Regenerative Medicine Drug Combinations Enhancing the Antineoplastic Effects of Erlotinib in High-Grade Glioma
Recent Patents on Anti-Cancer Drug Discovery Recent Progress in the Development of Fluorometric Chemosensors to Detect Enzymatic Activity
Current Medicinal Chemistry CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes
Current Drug Targets On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Endothelial Cell Heterogeneity: A Developmental Biologist’s Perspective
Current Angiogenesis (Discontinued) Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target
Current HIV Research Impact of Environmental Endocrine Disruption on the Reproductive System for Human Health
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Hope for Intervertebral Disc Degeneration: Bone Marrow Mesenchymal Stem Cells and Exosomes Derived from Bone Marrow Mesenchymal Stem Cell Transplantation
Current Gene Therapy Editorial (Thematic Issues: Advances in Developmental and Reproductive Toxicology)
Current Pharmaceutical Design